Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > anyone else hearing
View:
Post by lovingold on Oct 30, 2022 12:32pm

anyone else hearing

a buyout by a certain pharma in the range of $35m USD plus some contingency rights?
Comment by JDavenport on Oct 30, 2022 1:18pm
If something like that is imminent then one must wonder whether no deals have been allowed to happen during the "negotiation" period. In other words, would the pharma require Bioasis to enter no agreements until buyout terms are "negotiated," a word that I put in quotation markes for obvious reasons. Imagine, a deal for all of Bioasis for less than what xB3-001 is worth. Like ...more  
Comment by beenthere on Oct 30, 2022 7:26pm
Would not be the least interested in cvr!  Worth absolutely nothing! Have some of those! Ten years later and still worth nothing! Beenthere done that! Just a way to screw retail!
Comment by beenthere on Oct 30, 2022 8:50pm
Forget the cvr! $1.00US a share fully diluted! Minimum!
Comment by JDavenport on Oct 31, 2022 1:07am
One dollar? Fully diluted? You must mean fully deluded! Here's some interesting stuff. The current Corporate Presentation is only 17 pages long. They are as follows: 4 are about neither xB3 nor EGF. They just disclaimers, title page, etc. 2 are valuation pages comparing Bioasis's value to Denali and Annexon. 2 pages have information about both xB3 and EGF. 7 pages are about EGF. 2 pages ...more  
Comment by yureja55 on Oct 31, 2022 12:43am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities